Literature DB >> 25189308

Clinical characteristics, outcome and early induction deaths in patients with acute promyelocytic leukaemia: a five-year experience at a tertiary care centre.

Farheen Karim1, Usman Shaikh, Salman Naseem Adil, Mohammad Khurshid.   

Abstract

INTRODUCTION: Acute promyelocytic leukaemia (APL) is a distinct clinical and biological subtype of acute myeloid leukaemia. APL is notorious for causing early death during induction therapy, resulting in induction failure. The aim of our study was to report the clinical characteristics, outcome and early induction deaths with regard to patients with APL seen at our hospital.
METHODS: This was a retrospective study carried out at Aga Khan University Hospital, Karachi, Pakistan. Patients aged > 15 years diagnosed with APL within the period September 2007-September 2012 were included in the study.
RESULTS: Within the study period, 26 patients were diagnosed with APL based on morphology and the detection of t(15;17)(q24.1;q21.1) and promyelocytic leukaemia-retinoic acid receptor alpha (PML-RARA). The male to female ratio was 1:1. The median age of the patients was 41 (range 16-72) years. In all, there were 13 (50.0%) high-risk patients, and early induction death rate was 61.5%. Causes of early induction deaths (n = 16) included haemorrhage in 7 (43.8%) patients, differentiation (ATRA) syndrome in 7 (43.8%) and infection in 2 (12.5%). The survival rate among patients who survived the early period was 70% at 42 months. The relapse rate was 30%.
CONCLUSION: Early induction death rate was very high in patients with APL. The most common cause of early induction death in our study was haemorrhage. Outcome among patients with APL was found to be better among those who survived the initial period.

Entities:  

Mesh:

Year:  2014        PMID: 25189308      PMCID: PMC4294096          DOI: 10.11622/smedj.2014105

Source DB:  PubMed          Journal:  Singapore Med J        ISSN: 0037-5675            Impact factor:   1.858


  35 in total

Review 1.  Acute promyelocytic leukemia: evolving therapeutic strategies.

Authors:  Martin S Tallman; Chadi Nabhan; James H Feusner; Jacob M Rowe
Journal:  Blood       Date:  2002-02-01       Impact factor: 22.113

2.  Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome.

Authors:  Miguel A Sanz; Pau Montesinos; Chelo Rayón; Alexandra Holowiecka; Javier de la Serna; Gustavo Milone; Elena de Lisa; Salut Brunet; Vicente Rubio; José M Ribera; Concha Rivas; Isabel Krsnik; Juan Bergua; José González; Joaquín Díaz-Mediavilla; Rafael Rojas; Félix Manso; Gert Ossenkoppele; José D González; Bob Lowenberg
Journal:  Blood       Date:  2010-04-14       Impact factor: 22.113

3.  "Microgranular" acute promyelocytic leukemia: a distinct clinical, ultrastructural, and cytogenetic entity.

Authors:  H M Golomb; J D Rowley; J W Vardiman; J R Testa; A Butler
Journal:  Blood       Date:  1980-02       Impact factor: 22.113

4.  Meeting report. Acute promyelocytic leukemia-associated coagulopathy, 21 January 2004, London, United Kingdom.

Authors:  Martin S Tallman; Benjamin Brenner; Javier de la Serna; Hervé Dombret; Anna Falanga; Hau C Kwaan; Howard Liebman; Emmanuel Raffoux; Frederick R Rickles
Journal:  Leuk Res       Date:  2005-03       Impact factor: 3.156

5.  Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry.

Authors:  S Lehmann; A Ravn; L Carlsson; P Antunovic; S Deneberg; L Möllgård; A Rangert Derolf; D Stockelberg; U Tidefelt; A Wahlin; L Wennström; M Höglund; G Juliusson
Journal:  Leukemia       Date:  2011-04-19       Impact factor: 11.528

Review 6.  Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.

Authors:  Miguel A Sanz; David Grimwade; Martin S Tallman; Bob Lowenberg; Pierre Fenaux; Elihu H Estey; Tomoki Naoe; Eva Lengfelder; Thomas Büchner; Hartmut Döhner; Alan K Burnett; Francesco Lo-Coco
Journal:  Blood       Date:  2008-09-23       Impact factor: 22.113

Review 7.  Acute promyelocytic leukemia: from highly fatal to highly curable.

Authors:  Zhen-Yi Wang; Zhu Chen
Journal:  Blood       Date:  2008-03-01       Impact factor: 22.113

8.  International Society of Thrombosis and Hemostasis Scoring System for disseminated intravascular coagulation ≥ 6: a new predictor of hemorrhagic early death in acute promyelocytic leukemia.

Authors:  Mirjana Mitrovic; Nada Suvajdzic; Andrija Bogdanovic; Nada Kraguljac Kurtovic; Aleksandra Sretenovic; Ivo Elezovic; Dragica Tomin
Journal:  Med Oncol       Date:  2013-01-31       Impact factor: 3.064

9.  How I treat acute promyelocytic leukemia.

Authors:  Martin S Tallman; Jessica K Altman
Journal:  Blood       Date:  2009-12-10       Impact factor: 22.113

10.  All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol.

Authors:  Martin S Tallman; Janet W Andersen; Charles A Schiffer; Frederick R Appelbaum; James H Feusner; William G Woods; Angela Ogden; Howard Weinstein; Lois Shepherd; Cheryl Willman; Clara D Bloomfield; Jacob M Rowe; Peter H Wiernik
Journal:  Blood       Date:  2002-08-15       Impact factor: 22.113

View more
  5 in total

1.  Characteristics features and factors influencing early death in Acute promyelocytic leukemia; Experience from United Arab Emirates (UAE).

Authors:  Inaam Bashir Hassan; Mariam R Al Zaabi; Arif Alam; Mohammed Jawad Hashim; Martin S Tallman; Jorgen Kristensen
Journal:  Int J Hematol       Date:  2017-03-14       Impact factor: 2.490

2.  The evaluation of risk factors leading to early deaths in patients with acute promyelocytic leukemia: a retrospective study.

Authors:  Mehmet Baysal; Vildan Gürsoy; Fazil Cagri Hunutlu; Buket Erkan; Ufuk Demirci; Volkan Bas; Sedanur Karaman Gulsaran; Ibrahim Ethem Pinar; Tuba Ersal; Tugcan Alp Kirkizlar; Emine Ikbal Atli; Hakki Onur Kirkizlar; Elif G Ümit; Hakan Gürkan; Vildan Ozkocaman; Fahir Ozkalemkas; Ahmet Muzaffer Demir; Ridvan Ali
Journal:  Ann Hematol       Date:  2022-02-21       Impact factor: 3.673

3.  Coagulation Abnormalities and Risk Assessment in Acute Promyelocytic Leukemia: An Experience From a Resource-Constraint Country.

Authors:  Warkha Thakur; Nida Anwar; Naveena Fatima; Aisha Jamal; Quratul Ain Rizvi; Munira Borhany
Journal:  Cureus       Date:  2022-06-17

4.  Molecular and hematologic relapses in adult patients with acute promyelocytic leukemia: a cohort study.

Authors:  Ilana de França Azevedo; Michelline Gomes Magalhães; Fernanda Ribeiro Souto; Washington Batista das Neves; Fárida Coeli de Barros Correia Melo; Eduardo Magalhães Rego; Raul Antônio Morais Melo
Journal:  Rev Bras Hematol Hemoter       Date:  2016-10-21

Review 5.  RARG Gene Dysregulation in Acute Myeloid Leukemia.

Authors:  Maria Rosa Conserva; Immacolata Redavid; Luisa Anelli; Antonella Zagaria; Giorgina Specchia; Francesco Albano
Journal:  Front Mol Biosci       Date:  2019-10-24
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.